Metropolis Healthcare Limited has informed the Exchange about Sale of EQAS Division
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare has informed the stock exchange about the sale of its EQAS (External Quality Assessment Scheme) Division. EQAS is the part of the business that provides quality control and proficiency testing services to other pathology labs. The company has not yet disclosed the buyer, deal value, or timeline in this filing. Such a sale would streamline Metropolis's focus on its main diagnostic and pathology testing services. Shareholders will need to wait for further details on the financial impact and use of proceeds.
Divesting EQAS may help Metropolis sharpen focus on its core diagnostic business, but investors should watch for the deal value and whether the sale proceeds will be used for growth, debt reduction, or shareholder returns. Near-term stock reaction will depend on the price fetched for the division.